{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

Peer Baneke, MSIF CEO, attends German MS Society awards ceremony in Berlin

On 6 November MSIF’s CEO, Peer Baneke travelled to Berlin to witness the German MS Society’s, Deutsche Multiple Sklerose Gesellschaft Bundesverband e.V. (DMSG), annual awards ceremony.

read more

MSIF francophone member societies meet in Luxembourg, 10-11 October 2008

source: Ligue Française contre la Sclérose en Plaques

The annual meeting of MSIF’s French-speaking member societies took place on 10-11 October 2008, in Luxembourg.

read more

Inspiring others to join the movement - US National MS Society conference

Helen Regan, MSIF Advocacy and Communications Manager, joined 900 US National MS Society (NMSS) volunteers, fundraisers and NMSS staff for the 2008 annual conference, 5-7 November in Chicago, USA.

read more

back to top

Profile of the Month : January 2009

Raz Khatibi

Country: Iran
Age: 34
Type of MS: Secondary progressive
Year of diagnosis: 1997

I recommend that people overcome this disease and don't let it prevent them from their personal and social activities.

English Espanol Italiano Francais Deutsch Русский

read more

back to top

Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study

Medicines derived from cannabis have been tried for pain and spasticity in people with MS in trials. In this study the authors investigated the side effects of cannabinoid treatment. They found that side effects were not a problem at therapeutic doses but could be at higher doses.

authors: Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P, Pozzilli C, Inghilleri M

source: Clin Neuropharmacol. 2008 Oct 23

read more

Association of the PPARgamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis

The pathogenesis of MS is complex and genes play a role. In this study the authors found that certain genes involved in regulation of the immune system could also be involved in the age of onset of MS.

authors: Klotz L, Schmidt S, Heun R, Klockgether T, Kölsch H

source: Neurosci Lett. 2008 Oct 29

read more

The acute and chronic relapsing phases of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) are ameliorated by the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrinatoiron (III) chloride, (FeTPPS)

In MS the pathology may involve chemical reactions called oxidation. In this study the authors investigated the effects of a molecule which prevents oxidation in experimental animal models. They found benefits when it was given before the disease started, which is hopeful but future studies are now required in people.

authors: Bolton C, Scott GS, Smith T, Flower RJ

source: Eur J Pharmacol. 2008 Oct 22

read more

Mastery, functional disability and perceived health status in patients with multiple sclerosis

People with MS sometimes live with some level of disability, which may be due not only to physical dysfunction but also to mood disturbances. In this study the authors found that people with effective control strategies coped better with both physical and mood symptoms, and this was especially important in older people.

authors: Krokavcova M, Nagyova I, van Dijk JP, Rosenberger J, Gavelova M, Middel B, Gdovinova Z, Groothoff JW

source: Eur J Neurol. 2008 Nov;15(11):1237-44

read more

Effects of rivastigmine on memory and cognition in multiple sclerosis

In this placebo-controlled clinical trial the effects of rivastigmine in people with MS with cognitive dysfunction were tested. No significant benefits of the medication were observed and both the placebo and treatment groups improved during the study.

authors: Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N

source: Can J Neurol Sci. 2008 Sep;35(4):476-81

read more

back to top

US Election of Barack Obama source of hope for people with MS across the world

Barack Obama, the US President-elect, has a personal connection with MS as his wife's father had the condition.

read more

Apply now for European Neurological Society ‘Young Neurologist in Training Offer’ for Attendance to the 19th ENS Meeting in Milan

source: European Neurological Society

The ENS is offering grants to support young neurologists to attend the 19th European Neurology Society (ENS) Meeting, in Milan, Italy, June 20-24, 2009.

read more

Biogen reports another Tysabri brain disease case

source: MS Trust UK

Biogen Idec Inc has notified regulators of a new case of a potentially deadly brain disease in an MS patient being treated with Tysabri in the USA.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.